Kornimate/medical-research-clean huggingface dataset:
increasing exercise and decreasing sedentary behavior among patients in a cardiac rehabilitation clinic

Conditions: Acute Coronary Syndrome; Heart Failure; Other Cardiac Conditions Among Cardiac Rehabilitation Participants

Summary: cardiac rehabilitation patients often fail to exercise as prescribed on days they are not attending rehabilitation and there is a steep drop off in exercise following rehabilitation completion. moreover, little is known about the amount of time that cardiac rehabilitation patients spend in sedentary behavior, which is associated with increased risk of cardiovascular morbidity and mortality, independent of time spent in exercise. this pilot study aims to test acceptability, feasibility, and preliminary efficacy of a smartphone application (b-mobile-cardiac) for increasing time spent in moderate-to-vigorous intensity physical activity accumulated in bouts of at least 10 minutes in duration (i.e. bout-related mvpa) and decrease time spent in sedentary behavior. up to 32 patients will be recruited, enrolled, and randomized during the first 2 weeks of cardiac rehabilitation to either: 1) b-mobile-cardiac plus cardiac rehabilitation or 2) cardiac rehabilitation alone. participants will complete 7 days of objective activity monitoring to measure daily minutes spent in bout-related mvpa and sedentary behavior (primary outcomes) at baseline, mid-rehabilitation (6 weeks), end of cardiac rehabilitation (12 weeks), and 4-week follow-up (16 weeks). at these same time points, participants will complete questionnaires assessing sedentary behavior, mvpa, exercise tolerance, health-related quality of life, mood, and affect. at baseline and end of cardiac rehabilitation participants will undergo a blood draw to measure cardiometabolic and inflammatory risk factors and complete a test of cognitive functioning. feasibility and acceptability of the b-mobile-cardiac application will be assessed at the 4-week follow-up.


Eligibility criteria:
inclusion criteria: 1. within one week of starting rehabilitation, 2. self-report that they can walk for 10 minutes without assistance from others, 3. were approved for and are planning to complete 12 weeks of rehabilitation, 4. own a compatible android phone or are willing to be taught to use one by study staff; 5. no evidence of cognitive impairment 6. able to speak and read english, 7. aged 18-75 years, 8. no known nickel allergy, and 9. willing to follow the protocol (e.g., carry a smartphone for 16 weeks). exclusion criteria: -
pneumatic retinopexy versus vitrectomy with gas for retinal detachment due to myopic macular hole

Conditions: Retinal Detachment

Summary: to undertake a prospective randomized clinical study for treating retinal detachment due to myopic macular holes, utilizing pneumatic retinopexy versus pars plana vitrectomy with gas tamponade.to determine the efficiency of pneumatic retinopexy with c3f8 in the treatment of retinal detachment due to myopic macular hole.

retinal detachment caused by macular hole predominantly happened in high myopic eyes. this is a common type of retinal detachment in asia and often seen in the old people aged around 50 \~ 60, mainly in female. treatment of retinal detachment due to macular holes has changed over the years, and several methods have been described. some surgeons have used transscleral diathermy or cryotherapy or laser photocoagulation and drainage subretinal fluid without sclera buckling, other surgeons have used radial silicone explants beneath the macular combined with cryo, diathermy or laser. this method entails the difficulty of placing sclera sutures far posterior, especially hazardous if there is a posterior staphyloma with very thin sclera. besides the technically difficult, the extensive macular scarring caused by different coagulations limited the functional result to peripheral vision only. because of this, it is not generally used in the initial treatment. in 1982, gonvers and machemer4 proposed a new treatment technique that combined pars plana vitrectomy (ppv), partial air-fluid exchange, and face down positioning for 24 hours. since then vitrectomy with gas tamponade become the most common procedure for retinal detachment with macular hole. in 1984, miyake performed a simple gas injection into the vitreous followed by a face-down position. the effective of this simplified method was then reported by many observers.but these studies may have insufficiency because of small sample, nonrandomized, no defined eligibility criteria for patients selection. intraocular gas tamponade with or without pars plana vitrectomy (ppv) has commonly been performed nowadays. we conducted a multicenter randomized controlled clinical trial to compare their anatomic results and visual outcomes of both surgical techniques, to estimate the efficiency of both surgical methods in the treatment of retinal detachment with myopic macular hole.

Eligibility criteria:
inclusion criteria: * retinal detachment due to myopic macular hole. * the ability to give informed consent and to return for follow-up visit for 12 months exclusion criteria: * retinal detachment with macular hole and peripheral hole/tear * retinal detachment with severe proliferative vitreoretinopathy * retinal detachment with choroidal detachment or rupture * traction retinal detachment due to retinal vascular disease * had vitrectomy in the past * macular hole without retinal detachment * foveal schiesis without retinal detachment * secondary macular hole with retinal detachment

Keywords: pneumatic retinopexy vitrectomy retinal detachment macular hole treatment multi-center retinal detachment due to myopic macular hole
a research study looking at how semaglutide works in people with type 2 diabetes in spain, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how semaglutide works in real world patients. participants will get semaglutide prescribed to them by their doctor. the study will last for about 6 to 8 months. participants will be asked to complete some questionnaires about their health and diabetes treatment. participants will complete these during their normally scheduled visits with their doctor.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * the decision to initiate treatment with commercially available semaglutide has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study * male or female, age 18 years or older at the time of signing informed consent * diagnosed with type 2 diabetes at least 12 weeks prior to inclusion * available and documented haemoglobin a1c (hba1c) value equal to or less than 12 weeks prior to initiation of semaglutide treatment exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * treatment with any investigational drug within 90 days prior to enrolment into the study * hypersensitivity to semaglutide or to any of the excipients
safety of preoperative oral administration of a high caloric drink with protein

Conditions: Postoperative Nausea and Vomiting

Summary: the purpose of the study is to determine whether the oral administration of a high caloric drink with protein decreases the postoperative nausea and vomiting in patients with dysgnathia.


Eligibility criteria:
inclusion criteria: * patients with surgery for dysgnathia exclusion criteria: * diabetes mellitus

Keywords: preoperative nutrition postoperative nausea and vomiting dysgnathia anesthesia
ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with genotype 1a or genotype 4 chronic hepatitis c virus (hcv) infection, with severe kidney impairment or end stage kidney disease

Conditions: Hepatitis C Virus (HCV)

Summary: this study evaluates the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without dasabuvir in adults with hepatitis c virus (hcv) genotype 1a (gt1a) or genotype 4 (gt4) infection and with severe kidney impairment or end-stage kidney disease.


Eligibility criteria:
inclusion criteria: * chronic hepatitis c virus (hcv) genotype 1a (gt1a) infection or genotype 4 (gt4) infection (hcv rna level greater than 1,000 iu/ml at screening). * females must be post-menopausal, of non-child bearing potential or practicing specific forms of birth control. * chronic kidney disease stage 4 or stage 5. exclusion criteria: * females who are pregnant or breastfeeding * positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) * hcv genotype performed during screening unable to genotype or co-infection with any other hcv genotype, no mixed genotypes. * abnormal laboratory tests * current enrollment in another investigational study * prior treatment with a direct acting antiviral agent (daa) containing regimen with the exception of interferon or pegylated interferon with or without ribavirin * current treatment with a direct acting antiviral agent (daa) containing regimen * any evidence of liver cirrhosis or liver cancer

Keywords: hepatitis c infection hepatitis c severe kidney disease chronic kidney disease genotype 1a genotype 4 treatment experienced interferon ifn pegifn
to evaluate the treatment effect of an anti-infective agent for different kinds of infections (0826-052)

Conditions: Infection; Pneumonia; Urinary Tract Infection

Summary: to collect clinical response data with the use of ertapenem in approved indications.


Eligibility criteria:
inclusion criteria: * male or female patients, 20 years of age or older * patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment * patients who required therapy prior to identification of cause of infection exclusion criteria: * patient has a concomitant infection that may interfere with the evaluation of the response to ertapenem * patient has an apache ii \> 30. * patient has an infection caused by pathogens resistant to ertapenem * patients with known allergy to ertapenem or other drugs in the same carbapenem class, beta - lactams, lidocaine or local anesthetics of the amide type * the patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)
study of ontak (denileukin diftitox) in cutaneous t-cell lymphoma (ctcl) patients

Conditions: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome

Summary: the purpose of this study is to compare the effectiveness of two dose levels of ontak (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous t-cell lymphoma.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed recurrent or persistent ctcl as determined by reference pathology lab; * patient must have had 1 to 3 prior ctcl therapies. repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. only 1 prior combination cytotoxic regimen is permitted. topical or systemic steroids are not considered a therapy; * interleukin-2 receptor (il-2r) expression on at least 20% of tumor cells as determined by immunohistochemistry. * stage ia - iii disease and unlikely to progress during the first month on study. life expectancy of at least 12 months. * measurable or evaluable disease. lymph node involvement no greater than ln2. no ctcl involvement of bone marrow. * no active cns disease, kidney or liver disease, significant pulmonary disease, or cardiac disease. * no systemic infections; * willingness to be randomized to a placebo treatment only arm; * ecog performance status 0 or 1; exclusion criteria: • patients must not have previously received treatment with dab389il-2 or dab486il 2 (previous candidate compound evaluated in a clinical setting).
predictor of advanced sub-clinical atherosclerosis (pasa) study

Conditions: Atherosclerosis

Summary: the study will evaluate the clinical utilization of skin cholesterol (sc) for cardiovascular risk assessment in asymptomatic individuals at low, intermediate and high risk based on framingham global risk estimates. preliminary studies have suggested that sc is an easy to measure, noninvasive marker of cardiovascular risk. this study is intended to provide further data in support of broader clearance by the food and drug administration for the use of sc as a tool to identify asymptomatic patients at increased risk of cardiovascular disease. currently, sc testing is cleared for use as part of risk assessment in subject suspected of having significant multi-vessel disease. the current study data will be used to support the use of sc testing as part of cardiovascular risk assessment in subjects without suspected coronary artery disease (cad).

* the primary objective of the study will be to determine the relationship between skin cholesterol levels and carotid artery intima-media thickness (cimt), a surrogate marker for atherosclerotic burden used as the "gold standard" comparator. * secondary objectives of the study will be to compare the skin cholesterol levels with other markers of cad as hdl cholesterol, apo b, hscrp, and lipoprotein-association phospholipase a2. * another objective is to determine the relationship between skin cholesterol levels and the presence of carotid plaques detected by ultrasound.

Eligibility criteria:
inclusion criteria: * informed written consent from the subject prior to testing. * males or females 30-80 years of age exclusion criteria: * 1. known coronary heart disease, (history of myocardial infarction, coronary bypass surgery, coronary angioplasty, or angina pectoris with a positive stress test or angiographic documentation) * known peripheral vascular disease (claudication with ankle-brachial index \< 0.9, angioplasty, or peripheral artery bypass procedure) * known cerebrovascular disease (stroke or tia with documented carotid or aortic atherosclerosis) * history of carotid artery endarterectomy or carotid artery surgery * diabetes mellitus (fasting glucose \> 126 mg/dl, on on insulin-reducing medications) * 10-year framingham risk of cardiac death or mi using atp iii calculator \>20% * subjects taking cholesterol-lowering medications * known hepatitis * known pregnancy * skin disease on either hand (e.g. eczema psoriasis, rash or broken skin)

Keywords: skin cholesterol carotid plaque carotid intima-media thickness
deep biopsy via endoscopic submucosal dissection in upper gi subepithelial tumors

Conditions: Benign Neoplasm; Pathology

Summary: upper gastrointestinal subepithelial tumors are frequently encountered during esophagogastroduodenoscopy. treatment plans for subepithelial tumors are determined by algorithms based on endoscopic ultrasonography images. however, endoscopic ultrasonography alone may not be able to diagnose and evaluate upper gastrointestinal sets with sufficient accuracy. adequate tissue samples are required to increase the diagnostic accuracy of subepithelial tumors. deep biopsy is method that normal mucosa was dissected using enodsocpi submucosal dissection technique and multiple endoscopic biopsies were performed. the investigators will perform deep biopsy in subepithelial tumor.


Eligibility criteria:
inclusion criteria: * patients with upper gi sets exclusion criteria: * none
efficacy and safety of sh t00660aa in treatment of endometriosis

Conditions: Endometriosis

Summary: the purpose of this study is to demonstrate safety and efficacy of sh t00660aa compared to placebo in the treatment of endometriosis

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * female patients with endometriosis-associated pelvic pain exclusion criteria: * pregnant or lactating women * history or suspicion of hormone dependent tumor * therapy resistant endometriosis * need for primary surgical treatment * any other conditions which forbid the participation.
serum regucalcin level and chronic hepatitis b

Conditions: Chronic Hepatitis b; Liver Fibrosis

Summary: this study, it was aimed to investigate the relationship between serum regucalcin level and liver fibrosis level in patients with chb infection.

chronic hepatitis b (chb) infection continues to be an important health problem due to its high morbidity and mortality. for this reason, it is very important to determine the appropriate timing to start antiviral therapy in patients with chb infection and to evaluate the stage of liver fibrosis in the treatment follow-up. liver biopsy is the gold standard for detecting liver fibrosis. although it is generally accepted to be a safe procedure, it can cause some serious complications. for this reason, in recent years, many studies have been conducted on new noninvasive tests in the evaluation of liver fibrosis. one of them is the serum regucalcin level. studies have shown that serum regucalcin levels increase in liver damage, but there is no study in the literature comparing liver fibrosis and serum regucalcin levels in chb infection. this study, it was aimed to investigate the relationship between serum regucalcin level and liver fibrosis level in patients with chb infection.

Eligibility criteria:
inclusion criteria: * being followed up with a diagnosis of chronic hepatitis b * not having a known history of liver disease who applied to our outpatient clinic for other reasons * having a liver biopsy * ≥18 years exclusion criteria: * \<18 years

Keywords: hepatitis b fibrosis regucalcin liver
behavioral treatments for anxiety and depression in veterans with parkinson's disease

Conditions: Parkinson Disease; Anxiety; Depression

Summary: behavioral treatments for anxiety and depression (behta-d) is a research study for anxiety and depression in individuals with parkinson's disease (pd). the research clinicians try to teach skills that may help participants cope with anxiety and depression in the context of parkinson's disease. research clinicians will also discuss ways improve management of parkinson's symptoms. other skills taught include how to relax, change thinking, add in meaningful pleasant activity.

components of evidence-based cognitive behavioral therapy (cbt) treatments from current manuals developed for depression and anxiety will be used to construct the 8-week treatment program. the flexibility of modular based treatment allows patients and counselors to personalize interventions and skills for managing anxiety and depressive symptoms. the first treatment session will be in-person. all following sessions will be provided by telephone. caregivers will have the option of being involved in 2 ways throughout treatment - as a "coach" to facilitate use of new skills by their loved one with pd and as a recipient of stress- management support. the scope of caregiver involvement will vary across patients, based on their preference. involved caregivers will be given the opportunity to participate in 1 telephone-based stress-management session and 1 follow-up call scheduled individually during the first 4 weeks of treatment.

Eligibility criteria:
inclusion criteria: 1. have a confirmed diagnosis of idiopathic parkinson's disease 2. have significant anxiety and/or depressive symptoms as indicated by a score of greater than 4 on the geriatric depression scale -15 or greater than 5 on the hospital anxiety and depression anxiety subscale exclusion criteria: patients will be excluded if they have cognitive impairment as indicated by the montreal cognitive assessment (moca \< 23) or if they have a condition that threatens their safety or life including suicidal intent, current psychosis, bipolar, substance abuse or impulse control disorders within the past month.

Keywords: parkinson disease anxiety depression
effect of simbrinza® suspension as an added therapy to travatan z®

Conditions: Ocular Hypertension; Open Angle Glaucoma

Summary: the purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (simbrinza® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin analogue (pga) monotherapy (travatan z®).

this study was divided into 2 sequential phases. the screening/eligibility phase included one screening visit and two eligibility visits, during which subjects washed out of all other intraocular pressure (iop)-lowering medications and dosed with travatan z®, 1 drop instilled in each eye once daily for 28 days. subjects who met all inclusion/exclusion criteria were randomized at the second eligibility visit. the treatment phase consisted of two on-therapy visits (week 2 and week 6).

Eligibility criteria:
inclusion criteria: * diagnosis of open angle glaucoma or ocular hypertension; * mean iop measurements in at least 1 eye (study eye) of ≥ 21 mmhg and \<32 mmhg at 8 am while on travoprost monotherapy at 2 consecutive visits (eligibility 1 and eligibility 2); * able to understand and sign informed consent form; * other protocol-defined inclusion criteria may apply. exclusion criteria: * women of childbearing potential who are pregnant, breastfeeding, or do not agree to use an adequate birth control method throughout the study; * any form of glaucoma other than open angle glaucoma or ocular hypertension; * severe central visual field loss; * chronic, recurrent, or severe inflammatory eye disease; * ocular trauma within the past 6 months; * ocular infection or ocular inflammation within the past 3 months; * best-corrected visual acuity score worse than approximately 20/80 snellen; * eye surgery within the past 6 months; * any condition, including severe illness, which would make the subject unsuitable for the study in the opinion of the investigator; * use of any additional topical or systemic ocular hypertensive medication during the study; * patients who, in the opinion of the investigator, cannot discontinue all iop-lowering ocular medication(s) per the appropriate washout schedule prior to eligibility 1 visit; * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma prostaglandin analogue brinzolamide brimonidine
dysport® adult upper limb spasticity

Conditions: Nervous System Disorders

Summary: the purpose of this research study is to assess the efficacy of dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.


Eligibility criteria:
inclusion criteria: * adult patients - post stroke or brain injury * modified ashworth scale ≥ 2 * ambulatory patients exclusion criteria: * previous treatment with botulinum toxin of any type within 4 months prior to study entry for any condition * physiotherapy initiated less than 4 weeks before inclusion * previous surgery, alcohol, phenol in upper limb * neurological/neuromuscular disorders which may interfere with protocol evaluations